

Methadone, QTc interval prolongation and torsade de pointes: Case reports offer the best understanding of this problem

W. Victor R. Vieweg, Mehrul Hasnain, Robert H. Howland, Thomas Clausen, Jayanthi N. Koneru, Christopher Kogut, Ericka L. Breden Crouse, Jules C. Hancox, Antony Fernandez and Ananda K. Pandurangi

Abstract: We reviewed the literature and found 31 adult cases and 1 newborn case of methadone-associated QTc interval prolongation and/or torsade de pointes (TdP). Parametric statistics may not be useful in studying this issue because methadone-associated TdP is a very rare event and, hence, “an extreme outlier” consistent with scalable randomness. We may have to rely upon narrative medicine in the form of case reports with all its limitations and hazards to provide our best understanding. We report risk factors for methadone-associated QTc interval prolongation and TdP based on review of published case reports. We believe both drug manufacturers and the FDA would better serve our patients and inform clinicians if they more readily reported drug-induced outliers such as methadone-associated TdP using a case report format.

Keywords: Drug-induced QTc interval prolongation, methadone, risk factors, torsade de pointes

Introduction

Our major aim is to identify risk factors for methadone-associated QTc interval prolongation and torsade de pointes (TdP) applying principles of narrative medicine in a case report format. Although drug-induced QTc interval prolongation may be a necessary precondition for methadone-induced/associated TdP, we argue that it is insufficient to explain TdP. We believe that the mix of biochemical/metabolic disturbances, genetic variation and structural changes combined with methadone-induced/associated QTc interval prolongation best explain TdP.

Methadone

Methadone is a synthetic opiate most commonly employed in addiction treatment (or opiate dependence) and pain management. In 2006, Drug and Alcohol Services Information System reported that in 2005, 235,836 persons received methadone either for opiate detoxification or maintenance [Drug and Alcohol Services Information System, 2006 <http://www.oas.samhsa.gov/2k6/otp/>

otp.htm]. Methadone’s primary mechanism of action is as a mu-receptor agonist that may work as an antagonist at the NMDA receptor [Anderson *et al.* 2000; Roxane Laboratories, 2003]. Methadone is lipophilic and has unpredictable pharmacokinetics with large patient variability in absorption, bioavailability, peak concentration and half-life. Its bioavailability can range from 36 to 100% and its half-life from 8 to 59 hours. Its duration of action may be prolonged due to its lipophilicity and ability to remain in the liver and other tissues [Roxane Laboratories, 2003].

hERG liability of methadone

A striking feature of drug-induced QTc interval prolongation and TdP is that virtually all clinically used drugs linked with these effects share in common an ability to inhibit channels that mediate the cardiac rapid delayed rectifier current, I_{Kr} —an ionic current that is important in regulating ventricular action potential duration [Witchel *et al.* 2000; Hancox *et al.* 2008]. *Human Ether-à-go-go-Related Gene (hERG)* encodes a protein (hERG)

Ther Adv Psychopharmacol
(2013) 3(4) 219–232

DOI: 10.1177/
2045125312469982

© The Author(s), 2013.
Reprints and permissions:
[http://www.sagepub.co.uk/
journalsPermissions.nav](http://www.sagepub.co.uk/journalsPermissions.nav)

Correspondence to:
W. Victor R. Vieweg, MD
Departments of Psychiatry
and Internal Medicine,
Virginia Commonwealth
University, Richmond,
Virginia, USA
VicVieweg@GMail.Com

Mehrul Hasnain, MD
Department of Psychiatry,
Memorial University,
St John’s, Newfoundland,
Canada

Robert H. Howland, MD
University of Pittsburgh
School of Medicine, Western
Psychiatric Institute
and Clinic, Pittsburgh,
Pennsylvania, USA

Thomas Clausen PhD
Norwegian Centre for
Addiction Research (SERAF),
University of Oslo, Oslo,
Norway

**Jayanthi N. Koneru,
MBBS, CCDS**
Department of Internal
Medicine, Division of
Cardiology and Cardiac
Electrophysiology, Virginia
Commonwealth University,
Richmond, Virginia, USA

Christopher Kogut, MD
Department of Psychiatry,
Virginia Commonwealth
University, Richmond,
Virginia, USA

**Ericka L. Breden Crouse,
PharmD, BCPP, CGP, FASCP**
Department of Pharmacy,
Virginia Commonwealth
University, Richmond,
Virginia, USA

Jules C. Hancox, PhD
School of Physiology and
Pharmacology and
Cardiovascular Research
Laboratories, Medical
Sciences Building, University
of Bristol, University Walk,
Bristol BS8 1TD, UK

Antony Fernandez, MD
Departments of Psychiatry
and Virginia Commonwealth
University and Mental Health
Service Line, Veterans
Administration Medical
Center, Richmond, Virginia,
USA

Ananda K. Pandurangi, MD
Department of Psychiatry,
Virginia Commonwealth
University, Richmond,
Virginia, USA

that mediates I_{Kr} [Sanguinetti *et al.* 1995; Trudeau *et al.* 1995]. Due to identified structural features, hERG exhibits a high susceptibility to pharmacological blockade [Sanguinetti *et al.* 2005; Hancox *et al.* 2008]. Similar to QTc prolongation, I_{Kr} /hERG blockade is a surrogate marker of *TdP* rather than a direct indicator of arrhythmogenicity; it is likely that it is the downstream consequences of I_{Kr} block, such as cellular early-after-depolarisations and augmented transmural dispersion of repolarisation that contribute to the genesis of *TdP* [Hancox *et al.* 2008]. Consequently, in preclinical drug safety testing any identified hERG-blocking tendency of an investigational drug (typically assessed through the study of hERG channels expressed in mammalian cell lines) must be considered alongside other preclinical information [Gintant, 2008; Hancox *et al.* 2008]. Analysis of the association between hERG/ I_{Kr} block and observed propensity of clinically used drugs to produce *TdP* has led to the recommendation of a provisional 'safety margin' for drugs undergoing evaluation based on the ratio of hERG/ I_{Kr} half-maximal inhibitory concentration (IC_{50}) and effective therapeutic plasma concentration (ETPC, unbound) [Redfern *et al.* 2003]. A 30-fold IC_{50} /ETPC safety margin has been suggested to be sufficient for most drugs, although it is recognised that mixed ion channel block can mitigate risk [Redfern *et al.* 2003; Gintant, 2008; Hancox *et al.* 2008].

In 1986, high concentrations of methadone were reported to slow depolarization rate and prolong duration of action potentials from sheep Purkinje fibers [Mantelli *et al.* 1986]. Methadone and its relative L- α -acetylmethadol (LAAM) were later (in 2002) reported to inhibit hERG, with respective IC_{50} values of 9.8 and 2.2 μ M [Katchman *et al.* 2002]. This study also related the observed IC_{50} values to maximal plasma concentrations (C_{max}) following therapeutic drug administration, obtaining IC_{50}/C_{max} ratios of 2.7 and 2.2 respectively for methadone and LAAM [Katchman *et al.* 2002]. hERG channel blockade by methadone and LAAM has been confirmed by a number of subsequent studies with reported IC_{50} values for methadone ranging between ~1.7 and 20 μ M [Kang *et al.* 2003; Kornick *et al.* 2003; Eap *et al.* 2007; Lin *et al.* 2009; Kuryshev *et al.* 2010; Zunkler *et al.* 2010]. Examination of the effects of these agents on other cardiac ion channels has suggested preferential block of hERG [Kang *et al.* 2003; Kuryshev *et al.* 2010] with some effects of methadone evident also on

hNav1.5 and hCav1.2 [Kuryshev *et al.* 2010] and with much weaker effects on other cardiac K^+ currents [Kuryshev *et al.* 2010] indicating that hERG/ I_{Kr} K^+ channels are those most likely to be linked to methadone-induced QT prolongation. This is consistent with *in vitro* data indicating methadone-induced prolongation of the QT interval of isolated perfused rabbit hearts [Katchman *et al.* 2006] and of action potentials from human stem-cell derived cardiomyocytes [Kuryshev *et al.* 2010]. The link between I_{Kr} /hERG and methadone-induced QT prolongation is supported by observations regarding stereoselective actions of methadone enantiomers [Eap *et al.* 2007, Lin *et al.* 2009]. Two independent studies have shown (S)-methadone to be more potent against hERG than is (R)-methadone [Eap *et al.* 2007; Lin *et al.* 2009] with IC_{50} values for hERG current block of 2 and 7 μ M respectively [Eap *et al.* 2007]. This correlates with reported observations: (i) that replacing (R,S) methadone with (R) methadone in patients receiving maintenance treatment reduces the QTc interval [Ansermot *et al.* 2010] and (ii) that CYP2B6 slow metabolizer status (which leads to impaired (S)-methadone metabolism) correlates with a higher QTc interval in patients receiving racemic methadone than is the case for extensive metabolizers [Eap *et al.* 2007]. I_{Kr} /hERG block by methadone may also be consistent with modestly increased QT-dispersion seen in some methadone-treated patients [Krantz *et al.* 2005].

The original report of hERG channel block by methadone and LAAM included comparison with other opioid agonists, with fentanyl and buprenorphine also exhibiting hERG block with IC_{50} values < 10 μ M, while codeine and morphine had little or no effect at therapeutically relevant concentrations [Katchman *et al.* 2002]. However, normalization of data to IC_{50}/C_{max} values yielded only low values (<3) for methadone and LAAM, with values of >50 for other agents studied [Katchman *et al.* 2002]. A separate study has compared methadone and heroin effects on hERG, reporting the latter to be ~100-fold less potent than methadone [Zunkler *et al.* 2010]. Chlorbutanol has been suggested to potentiate the ability of methadone to inhibit hERG current [Kornick *et al.* 2003] and diazepam has been suggested to exacerbate hERG-blocking effects of methadone by alleviating methadone block of sodium channels and, thereby, reducing any compensatory effect of sodium channel block on hERG inhibition [Kuryshev *et al.* 2010].

Case report format

Rather than attempting to develop a database that can be analyzed using parametric statistics, we employed the principles of narrative medicine in a case report format as we have in our other papers assessing psychotropic drug-induced QTc interval prolongation and *TdP* [Vieweg, 2003; Vieweg *et al.* 2004; Vieweg *et al.* 2005; Vieweg *et al.* 2009; Vieweg *et al.* 2012]. Data from our review of case reports in the literature and analyses of those data form the body of our paper.

Methods

On January 8, 2012, we entered “methadone and QT prolongation” (81 articles), “methadone and QTc” (71 articles) and then “methadone and *tor-sade*” (38 articles) into PubMed limiting our selections to those in English. From these findings, we found 20 case reports in the literature and 12 additional case reports referenced in this literature (one was not in English).

Results

Vital information from these 32 case reports appears in Table 1. Nineteen subjects were men (age 44.4 ± 12.9 , range 22–61 years). Twelve subjects were women (age 46.3 ± 7.0 , range 36–61 years). One subject was a female newborn.

Among the 21 subjects—nine men and 12 women—(Table 1—patients 1, 6, 7, 9–14, 18–28 and 31 cases are printed in red) (1) developing *TdP*, (2) having QTc interval measurements in close proximity to the time they developed this arrhythmia and (3) having daily methadone doses recorded at the time of *TdP*, there were insignificant correlations between QTc interval and methadone dose using both parametric and nonparametric statistics (Pearson $r = -0.263$, $p = 0.249$, Kendall's tau_b -0.39 , $p = 0.808$, Spearman's rho $= 0.005$, $p = 0.982$). When we assessed the correlation between methadone dose and total risk factors (Table 1), we again found an insignificant inverse relationship using both parametric and nonparametric statistics (Pearson $r = -0.084$, $p = 0.663$, Kendall's tau_b -0.46 , $p = 0.744$, Spearman's rho $= -0.071$, $p = 0.714$). (Even though all subjects received methadone and this drug constitutes a risk factor for QTc interval prolongation, we did not include methadone in our calculations of the relationship between methadone dose and total risk factors.) This is not a case control study and all statistical assertions made above have significant limitations. We discuss

these limitations further when we compare our findings with those from the literature in the discussion.

Major risk factors (Table 1) for QTc interval prolongation and *TdP* among the 31 adult methadone users in our sample included (1) female sex ($n=12$), (2) heart disease ($n=11$), (3) electrolyte imbalance [hypokalemia ($n=7$) and hypomagnesemia ($n=4$)], (4) metabolic (CYP) drug interactions ($n=19$), (5) concurrent use of medications associated with QTc interval prolongation ($n=14$), (6) hepatic impairment ($n=6$), (7) and other risk factors: sinus bradycardia ($n=8$) and cocaine ($n=6$). Twenty-four of 31 adult patients (77.4%) had multiple risk factors besides methadone. This observation may add importantly to understanding our data.

Discussion

Our two main findings (Table 1) were (1) using both parametric and nonparametric statistics, no obvious relationship between methadone dose and QTc interval prolongation in patients taking methadone and developing *TdP* and (2) the common finding of multiple risk factors for *TdP* present in patients taking methadone without any obvious correlation between methadone dose and number of risk factors. The risk factors we identified (Table 1) were similar to those previously reported among methadone patients [Krantz *et al.* 2002; Hanon *et al.* 2010] and patients taking non-cardiac drugs [Viskin *et al.* 2003]. In non-methadone psychotropic drug-induced/associated *TdP*, two women appear for every man. Among the elderly with this problem, women may represent up to 90% of the cases [Vieweg *et al.* 2009]. However, adult men appeared more commonly than women in our study (19 *versus* 12).

Predicting methadone-induced QTc interval prolongation and TdP

Investigators have proposed large subject sizes to predict methadone-induced QTc interval prolongation and associated *TdP* [Cruciani, 2008], but such recommendations assume that parametric statistics apply in this setting and this appears to be a false assumption [Taleb, 2010]. Methadone exposure may link to increased sudden cardiac death (SCD) in the community even among those with therapeutic levels of methadone [Chugh *et al.* 2008]. QTc interval prolongation, when it reaches 500 msec or more, predicts a population vulnerable to polymorphic ventricular tachycardia and its

better known subtype *TdP* [Vieweg *et al.* 2009, Vieweg *et al.* 2011]. However, the rarity of these arrhythmias precludes using QTc interval prolongation alone to quantitate the risk of drug-induced SCD.

Anchersen *et al.* [2009] reported the prevalence of QTc interval prolongation among subjects in opioid maintenance treatment and the potential mortality associated with QTc interval prolongation in the Norwegian opioid maintenance treatment program. Among the 173 patients receiving methadone, 4.6% had QTc interval >500 msec (all taking methadone ≥ 120 mg), 15% had QTc interval >470 msec and 28.9% had QTc interval >450 msec. The authors found a positive dose-dependent relationship between methadone dose and QTc interval lengthening (Pearson $r=0.37$, $p<0.01$; multiple regression analysis $B=0.37$, $p<0.01$). A case control study was not performed. During the first month of methadone maintenance treatment, two deaths occurred among 3850 initiations of methadone maintenance. One patient died from intracranial bleeding and one cause of death was unknown. Anchersen *et al.* [2009] concluded that death due to methadone during the first month of treatment was low and did not exceed 0.06 per 100 patient-years. The authors did not report the presence or absence of risk factors associated with *TdP* and attendant QTc interval prolongation in this paper but did look at their patients with QTc interval >500 msec in a second paper [Anchersen *et al.* 2010].

Anchersen *et al.* [2010] provided a detailed review of their earlier subjects with QTc interval >500 msec with a particular focus on risk factors. Assessment included a detailed medical and cardiac history, genetic testing for the five most common long QT syndrome mutations, cardiac exercise testing and 24-hour Holter monitor records. The authors assessed seven subjects and found that two were heterozygous long QT syndrome mutation carriers who had both experienced cardiac complaints before and during opioid maintenance treatment. The authors detected no additional risk factor among these seven patients. In six subjects, QTc intervals fluctuated widely during 24-hour Holter monitor recording and exercise testing [Anchersen *et al.* 2010].

Methadone-associated QTc interval prolongation

More than 80% of patients receiving long-term methadone maintenance therapy may have QTc

interval prolongation compared with reference values for patients of the same age and sex and there may be no correlation between QTc interval measurement and methadone dose [Maremmani *et al.* 2005]. However, others have reported a positive relationship between methadone dose and QTc interval duration [Kornick *et al.* 2003; Krantz *et al.* 2003]. Among our 21 cases of methadone-associated *TdP*, we failed to identify any relationship between QTc interval prolongation and methadone dose. Perhaps, multiple risk factors present may explain this finding.

A paper recently published by Roy *et al.* [2012] studied 180 subjects (69.1% men) in a methadone maintenance therapy program. Mean QTc interval was 420.9 ± 21.1 msec and the mean daily methadone dose was 80.4 ± 27.7 mg. There was no significant correlation between these two measurements ($p = 0.33$) with 8.8% of patients demonstrating QTc interval prolongation (8.3% men and 0.5% women).

In contrast to the uneven findings of the relationship between QTc interval prolongation among *TdP* patients and methadone dose in our and other studies, Miceli *et al.* [2010] found a significant positive correlation between therapeutic doses of both ziprasidone and haloperidol and QTc interval measurements in 59-medically-healthy adults with either schizophrenia or schizoaffective disorder in a well-controlled study. No patient developed QTc interval of ≥ 450 msec. Several factors distinguished the Miceli *et al.* paper from the methadone papers: (1) QTc interval measurements related positively to antipsychotic drug dose (i.e., the higher the drug dose, the greater the QTc interval), (2) neither ziprasidone nor haloperidol administrations were associated with QTc interval prolongation or *TdP* and (3) no risk factors for QTc interval prolongation were present such as drugs that inhibited antipsychotic drug metabolism or linked to QTc interval prolongation itself.

Case series in the literature

Krantz *et al.* [2002] reported 17 patients (mean QTc interval 615 ± 77 msec on presentation) who developed *TdP* while taking methadone (mean daily dose 397 ± 283 mg). Their data were tabulated but did not contain the breadth and depth of information found in a case report format. The authors concluded that very-high-dose methadone might cause *TdP*. The next year, Krantz

et al. [2003] reported the dose-related effects of methadone on QTc interval prolongation in their 17 patients with methadone-associated *TdP*. Only the daily dose of methadone predicted the QTc interval ($r=+0.51$, $p=0.03$). They did not conduct a case control study.

Hanon *et al.* [2010] reported a retrospective case series of 12 consecutive patients (mean daily methadone dose 135 mg) hospitalized with methadone-induced QTc interval prolongation and *TdP* during the study period July 2007 to April 2009. Their hospital was the only referral source for 6500 methadone maintenance patients. Thus monthly (21 months), 12/21 (0.57) of 6500 ($0.57/6500=0.0000879$) or 8.8×10^{-5} patients experienced changes sufficient to produce *TdP* and live long enough to be hospitalized. (Daily risk would be $8.8/30 \times 10^{-5}$ or 2.9×10^{-6} patients or about 3 episodes of *TdP* daily per 1 million methadone maintenance treatment patients.) The authors did not say how many of these 6500 patients experienced SCD outside the hospital.

Sex differences in methadone exposure and QTc interval prolongation

We found, as did others [Hanon *et al.* 2010], that men are more commonly involved in cases of methadone-associated QTc interval prolongation and *TdP* than women. This contrasts to many observations that women are more commonly involved in non-cardiac drug-associated QTc interval prolongation and *TdP* than are men [Vieweg *et al.* 2009; Vieweg *et al.* 2011]. With the onset of puberty, the QT interval shortens for men by about 20 msec (androgen effect) compared with women.

Chang *et al.* [2011] performed a cross-sectional analysis of low-dose methadone and sex effects in 283 heroin-dependent patients (229 men and 54 women) undergoing QTc interval measurement 59 days (interquartile range: 36 to 288 days) after starting methadone treatment. To assess methadone over time, a 150-patient subset (126 men and 24 women) underwent QTc interval assessment before and 37 days (interquartile range 32-44 days) after starting methadone therapy. Methadone dose-QTc interval correlation was significant for men ($r=0.210$, $p=0.0014$) but not for women ($r=0.164$, $p=0.2363$). Over six-months, 60.7% of patients developed an increase in their QTc interval compared with baseline measurements. QTc interval significantly increased in men (from 418.5

to 426.9 msec, $p<0.0001$) but not in women (from 437.7 to 441.1 msec, $p=0.468$). The authors concluded that (1) low-dose methadone treatment demonstrates dose-dependent QTc interval prolongation and links to significant QTc interval lengthening within six months of starting methadone treatment and (2) men are more susceptible than women are to low-dose methadone-associated QTc interval prolongation.

Martell *et al.* [2005] prospectively assessed methadone (20-200 mg/day) effects on QTc intervals in 160 patients possessing varying numbers of risk factors for QTc interval prolongation. Women had significantly longer QTc intervals than men at baseline did. At six-month follow-up, however, factors associated with greater QTc interval prolongation included male sex and methadone dose at which time 13% of men and 11% of women demonstrated QTc interval prolongation. At 12-month follow-up, methadone dose marginally linked to greater QTc interval prolongation at which time 20% of men and 2% of women showed QTc interval prolongation. No cases of *TdP* appeared in this study. Their work [Martell *et al.* 2005] coupled with others [Maremmani *et al.* 2005; Sticherling *et al.* 2005] suggest that more than 80% of patients in methadone maintenance programs have some degree of QTc interval prolongation as discussed earlier.

Men are more likely to abuse drugs than women are. Zickler [2000] traces this finding to opportunities to use drugs of abuse. This observation applies to heroin abusers and, therefore, subsequent abusers requiring methadone maintenance therapy. Among our adults, 19 of 32 case reports (59.4%) involved men (Tables 1). In the Hanon *et al.* [2010] series, 9 of 12 (75%) cases were men. In the Chang *et al.* [2011] series, 229 of 283 (80.9%) subjects were men. If methadone was the main risk factor for *TdP* and uniformly led to QTc interval prolongation among women and men in the cases under discussion, we would expect this drug to maintain the 2:1 F:M ratio found in non-methadone psychotropic drug-induced cases of QTc interval prolongation and *TdP* [Vieweg *et al.* 2009; Vieweg *et al.* 2011]. We believe the preponderance of male methadone cases is because men are much more likely than women to require methadone treatment for a variety of reasons and this findings overrides greater female vulnerability to drug-induced QTc interval prolongation and *TdP* [Makkar *et al.* 1993].

Risk factors for QTc interval prolongation and TdP

We have reviewed risk factors for QTc interval prolongation and TdP previously [Vieweg *et al.* 2009]. Electrolyte disturbances [particularly hypokalemia (commonly diuretic-induced) and hypomagnesemia (commonly found during hospitalization in general and intensive care units [Agus, 1999]) and among alcoholics [Backmund *et al.* 2003]] are among these risk factors [Arbel *et al.* 2007; Hanon *et al.* 2010].

Bednar *et al.* [2001] in their Table 2 identified 16 factors prolonging the QTc interval. Those risk factors included (1) congenital, (2) increasing age, (3) female sex, (4) meals, (5) sleep, (6) drugs, (7) obesity/weight gain, (8) liquid protein diet, (9) alcoholism, (10) electrolyte disturbances (hypokalemia, hypomagnesemia, hypocalcemia), (11) hypoglycemia/diabetes mellitus, (12) myocardial ischemia and infarction, cardiomyopathy, (13) hypertension, (14) hypothyroidism/pituitary insufficiency, (15) central nervous system insult: stroke, subarachnoid hemorrhage, trauma, infection, tumor and (16) cirrhosis.

Viskin *et al.* [2003] in their review (Figure 3 derived from 229 published cases) of the long QT syndrome caused by noncardiac drugs identified seven major risk factors in order of greatest to least as follows: (1) female sex, (2) heart disease, (3) hypokalemia, (4) toxic drug levels, (5) drug interactions involving the QT interval, (6) metabolic drug interactions and (7) familial history of long QT syndrome. The authors found that 96% of their study subjects had one or more risk factors, 72% had two or more risk factors and 39.5% had three or more risk factors. In our Table 1, we slightly modified this list to include (1) female sex, (2) heart disease, (3) hypokalemia/hypomagnesemia, (4) drug interactions involving the QT interval and metabolic drug interactions, (5) hepatic impairment and (6) others including sinus bradycardia and cocaine.

High-dose methadone (120 mg/day and above)

The United Kingdom methadone treatment guidelines [Department of Health (England) and the Devolved Administrations, 2007] recommend obtaining an EKG in persons taking greater than 100 mg of methadone per day. Anchersen *et al.* found an association with dosages ≥ 120 mg and QTc interval > 500 msec [Anchersen *et al.* 2009].

Twenty-three of our 31 adults (74.2%) were exposed to daily methadone doses of 120 mg or greater (Table 1). In the Hanon *et al.* [2010] series, seven of 12 subjects (daily dose range 35 to 250 mg) received daily doses of methadone 140 mg or greater. In contrast to daily methadone doses of up to 700 mg daily (our Table 1), these patients were exposed to no more than 250 mg of methadone/day. In our sample, seven cases (25.8%) experienced QTc interval prolongation at doses less than 120 mg per day, with the lowest dosage reported being only 40 mg of methadone. Even though a methadone dose effect on QTc interval lengthening may appear [Krantz *et al.* 2003; Chang *et al.* 2011], its clinical utility is highly questionable [Cruciani, 2008].

Drug interactions

Co-administration of methadone metabolic inhibitors. Methadone is metabolized hepatically by N-demethylation via cytochrome P-450 isoforms, primarily CYP3A4, CYP2B6, CYP2C19 and to a lesser degree by CYP2C9 and CYP2D6. Co-administration of methadone with enzyme inducers may cause more rapid methadone metabolism potentially decreasing methadone effects. Co-administration of CYP inhibitors may slow metabolism thereby potentiating methadone's effects. When coadministering methadone with drugs known to both induce and inhibit CYP enzymes, its pharmacokinetics may change unpredictably. Antiretroviral drugs such as efavirenz, nelfinavir, nevirapine, ritonavir and lopinavir + ritonavir combination will inhibit some CYPs. These drugs may also reduce methadone plasma levels due to CYP induction. Therefore, always evaluate drugs concomitantly administered with methadone for their interaction potential and evaluate individual response to drug therapy before adjusting the dose [Anderson *et al.* 2000; Roxane Laboratories, 2003].

Although methadone is primarily metabolized by CYP3A4, CYP2B6 and CYP2C19 are also important in methadone metabolism. CYP3A4 metabolic inhibitors administered to our 31 adult patients (Table 1) included fluoxetine ($n=2$), cannabinoids ($n=4$), clarithromycin ($n=1$), cotrimoxazole (sulfamethoxazole/trimethoprim) ($n=3$), fluvoxamine ($n=1$), protease inhibitors ($n=3$), ciprofloxacin ($n=1$), itraconazole ($n=1$) and voriconazole ($n=2$). CYP2B6 metabolic inhibitors administered to our 31 adult patients (Table 1) included sertraline and ritonavir, a protease

Table 1. Case report risk factors for QTc interval prolongation and *torsade de pointes* (TdP) Cases in red formed the 21 patients allowing a correlation between QTc interval prolongation and methadone dose. Based on current evidence reviewed in this paper, risk factors in addition to methadone are tabulated and include (1) female sex [n=12], (2) heart disease [n=11], (3) electrolyte imbalance [hypokalemia (n=7) and hypomagnesemia (n=4)], (4) metabolic drug interactions [CYP inhibitors (CYP) [n=19], (5) concurrent use of medications associated with QTc interval prolongation [QTc prolonging (QTP) [n=14], (6) hepatic impairment [n=6] and (7) other risk factors: bradycardia [n=8][Brachmann *et al.* 1983] and cocaine [n=6][Magnano *et al.* 2006].

Case & Citation	QTc msec	Methadone mg/day	TdP	Age Years	Sex M/F	Heart disease	Electrolytes imbalance ↓K, ↓Mg	Interacting drugs CYP inhibitors (CYP) QTc prolonging (QTP)	Hepatic impairment	Other risk factors	Total #
1[Deamer <i>et al.</i> 2001]	710	120	Yes	41	F		↓Mg	Cannabinoids (CYP3A4), Fluoxetine (CYP2D6, CYP2C19, CYP3A4, QTP)			5
2[Walker <i>et al.</i> 2003]	Prolonged	660	Yes	41	F		↓K	Fluoxetine (CYP2D6, CYP2C19, CYP3A4, QTP)			4
3[Walker <i>et al.</i> 2003]	Prolonged	650	Yes	52	F	Yes					2
4[Walker <i>et al.</i> 2003]	Prolonged	700	Yes	61	F	Yes		Sertraline (CYP2B6, CYP2C19)			3
5[Vodoz <i>et al.</i> 2003]	Prolonged	200	Yes	25	M	Yes					1
6[Gil <i>et al.</i> 2003]	600	275	Yes	36	M	Yes		Cotrimoxazole (CYP3A4, QTP)			3
7[Gil <i>et al.</i> 2003]	640	300	Yes	39	M	Yes		Clarithromycin (CYP3A4, QTP)		Sinus bradycardia	4
8[Gil <i>et al.</i> 2003]	640	385	?	34	M					Sinus bradycardia	1
9[Gil <i>et al.</i> 2003]	510	700	Yes	31	M	Yes		Cotrimoxazole (CYP3A4, QTP), Fosfarnet (QTP)			4
10[Almehmi <i>et al.</i> 2004]	549	700	Yes	51	M		↓K ↓Mg				2
11[Krantz <i>et al.</i> 2005]	582	450	Yes	42	M			Fluvoxamine (CYP3A4)			1
12[Krantz <i>et al.</i> 2005]	635	80	Yes	46	F	Yes	↓K			Cocaine	4

Table 1. (Continued)

Case & Citation	QTc msec	Methadone mg/day	TdP	Age Years	Sex M/F	Heart disease	Electrolytes imbalance ↓K, ↓Mg	Interacting drugs CYP inhibitors (CYP) QTc prolonging (QTP)	Hepatic impairment	Other risk factors	Total #
13[Lüthi et al. 2007]	654	150	Yes	53	F		↓K		Yes		4
14[Routhier et al. 2007]	517	145	Yes	52	F	Yes	↓Mg ↓K		Yes	Cocaine	5
15[Hussain et al. 2007]	510	In utero exposure	No	0	F*					Sinus bradycardia	1*
16[Sekine et al. 2007]	591	240	No	59	M						0
17[Wong et al. 2007]	516	375	No	22	M					Sinus bradycardia, cocaine	2
18[Falconer et al. 2007]	555	105	Yes	34	M			Protease Inhibitors: Atazanavir (CYP3A4) and Ritonavir (CYP3A4, CYP2B6)	Yes	Sinus bradycardia	4
19[Iskandar et al. 2007]	605	160	Yes	43	F	Yes					2
20[Abramson et al. 2008]	600	230	Yes	47	F			Amiodarone (QTP)	Yes		3
21[Pimentel et al. 2008]	577	135	Yes	40	F						1
22[Esses et al. 2008]	580	100	Yes	56	M						0
23[Prosser et al. 2008]	690	125	Yes	57	M	Yes		Voriconazole (CYP3A4, QTP), Cannabinoids (CYP3A4)		Sinus bradycardia, cocaine	6
24[Nair et al. 2008]	538	120	Yes	56	M		↓K	Ciprofloxacin (CYP3A4, QTP)	Yes		4

Table 1. (Continued)

Case & Citation	QTc msec	Methadone mg/day	TdP	Age Years	Sex M/F	Heart disease	Electrolytes imbalance ↓K, ↓Mg	Interacting drugs CYP inhibitors (CYP) QTc prolonging (QTP)	Hepatic impairment	Other risk factors	Total #
25[Reinhold <i>et al.</i> 2009]	600	125	Yes	57	M	Yes		Voriconazole(CYP3A4, QTP), Cannabinoids (CYP3A4), Amiodarone (QTP) Itraconazole (CYP3A4)		Sinus bradycardia, cocaine	7
26[Noorzurani <i>et al.</i> 2009]	520	120	Yes	44	F						2
27[Puri <i>et al.</i> 2009]	540	70	Yes	36	F						1
28[John <i>et al.</i> 2010]	550	40	Yes	50	M			Cotrimoxazole (CYP3A4, QTP), Protease inhibitor: Atazanavir (CYP3A4)	Yes	Cocaine	2
29[De Jong <i>et al.</i> 2011]	600	Unknown	Yes	52	M						2
30[Nordt <i>et al.</i> 2011]	569	Unknown	Yes	55	M			Amiodarone (QTP), Doxepin (QTP)			2
31[Thanavaro <i>et al.</i> 2011]	626	110	Yes	61	M		↓K ↓Mg				2
32[Calver <i>et al.</i> 2012]	480	120	No	27	M			Cannabinoids (CYP3A4)		Sinus bradycardia	2

*Female sex not a risk as patient was an infant.

inhibitor. CYP2C19 inhibitors included fluoxetine and sertraline.

Concomitant administration of drugs that may prolong the QTc interval may lead to QTc interval prolongation and *TdP*. Medications with the potential to prolong the QTc interval in our 31 adult patients (Table 1) included amiodarone ($n=3$), ciprofloxacin ($n=1$), cotrimoxazole ($n=3$), doxepin ($n=1$), foscarnet ($n=1$), fluoxetine ($n=2$) and voriconazole ($n=2$).

Multiple risk factors and TdP among subjects exposed to methadone

Among the 27 case reports involving *TdP* (Table 1), 22 (81.5%) had multiple risk factors for this potentially fatal cardiac arrhythmia—that is, risk factors in addition to exposure to methadone. This characteristic has been reported by others and our group previously [Zeltser *et al.* 2003; Vieweg *et al.* 2009].

Zeltser *et al.* [2003] reviewed risk factors for *TdP* among subjects taking non-cardiac drugs. They asserted that these risk factors (female sex, heart disease, electrolyte imbalances, excessive dosing, drugs interactions and family history of long QT syndrome) are easily identifiable from the medical history and/or clinical evaluation. In their review, they identified 249 subjects with *TdP* associated with non-cardiac drugs. Female sex was the most common risk factor (71%), almost all of their subjects had at least one risk factor and 71% had two or more risk factors. The authors concluded clinicians planning to prescribe non-cardiac drugs associated with *TdP* could easily identify risk factors for *TdP* before prescribing the culprit drug. Unfortunately, Zeltser *et al.* do not report how often the culprit drug is prescribed for patients with risk factors for *TdP* and yet it does not occur—hence, a major problem in estimating risk.

Included in risk factors for *TdP* may be acute structural cardiac changes in certain settings. Crotti *et al.* [2012] recently described *TdP* following acute myocardial infarction (AMI) in a genetic substrate predisposed to a time-limited development of life-threatening ventricular tachyarrhythmias. The authors studied 13 patients who developed *TdP* during the subacute phase of AMI. The comparison group constituted 133 ethnically-matched controls with uncomplicated AMI. They screened for long QT syndrome genes

and the *KCNH2-K897T* polymorphism. They found that two of the 13 patients presenting with QTc interval prolongation and *TdP* carried long QT syndrome mutations (*KCHN2-R744X* and *SCN5A-E446K*). Nine of the remaining 11 patients carried the *KCNH2-K897T* polymorphism as did 35% of controls ($p=0.0035$). The authors concluded that AMI patients carrying the *KCNH2-K897T* polymorphism are eight times more likely to develop *TdP* than controls. Administration of methadone or any other drug associated with QTc interval prolongation in this setting likely would further increase the risk of developing *TdP*.

Scalable randomness and predicting drug-induced TdP. Raschi *et al.* [2009] recently reviewed models for predicting hERG liability (I_{Kr} blockade) and QT interval prolongation. They reported that 40 to 70% of new model entries considered as potential therapeutic drugs are abandoned early in development because they test positive for hERG blocking liability. However, lack of hERG blocking liability does not preclude a drug from linking to QTc interval prolongation and *TdP*.

Our study suggests that QTc interval prolongation in the setting of *TdP* is not linked to methadone dose, is not predictable at present and may not be Gaussian in distribution. Raschi *et al.* [2009] identified many risk factors underlying drug-induced *TdP* onset including organ impairment, drug interactions, electrolyte imbalance and genetic mutations leading to reduced repolarization reserve. Additional mechanisms and mathematical models are probably operative—especially Chaos theory [Gleick, 1987]. Minute differences in the initial conditions (genetic makeup, medication profile, electrolytes, structural abnormalities, etc.) tend to evolve into extraordinarily different outcomes (slight QT prolongation vs *TdP*) when exposed to methadone. We believe that any useful effort to predict methadone-associated *TdP* and attendant QTc interval prolongation must better understand the role of the above-identified risk factors in *TdP*.

Taleb [2010] discussed the concept of scalable randomness citing an example as follows. Expect a project to be finished in 79 days. If not completed, anticipate another 25 days. However if the project remains unfinished by the 90th day, it should take another 58 days to complete. On the 100th day, it should have 89 days to completion and on the 119th day, it will have another 149 days

to go. If not finished by the 600th day, an additional 1590 days will be necessary. It follows that added and unanticipated complexity drives each delay. Similarly, added and unanticipated risk factors appear in patients destined to develop *TdP* independent of the original drug prescribed. If so, the QTc interval-prolonging drug may be a prerequisite but not sufficient without additional risk factors to best explain drug-associated *TdP*. It follows that multiple risk factors including the drug itself add complexity and uncertainty sufficient to negate parametric statistics as an approach to studying this problem.

What to do with our data and similar data from the literature?

Heroin dependency was the most common indication for methadone administration among our 31 adult subjects (Table 1). Twenty-four of them (77.4%) received methadone to treat heroin dependence and seven (22.6%) received methadone for pain relief. These are the two most common indications for methadone administration and simply tell us that any patient taking methadone may be at risk for *TdP*. The rarity of *TdP* among methadone users precludes knowing how many methadone users do not develop *TdP* and what factors separate these two groups. Therefore, we must study the published data on the subject via the case report format to learn as much as possible about *TdP*. Unfortunately, both the FDA and drug manufacturers tend not to make case report material available compounding the effort to better understand the relationship between psychotropic drugs and *TdP* in general and the relationship between methadone and *TdP* in particular.

Study limitations

The most obvious study limitations are data derived from case reports and the inability to provide risk estimates. Narrative medicine in the form of case reports is inherently selective and may or may not provide representative data of clinical relevance to the medical issues discussed. Studying extreme outliers (Black Swans [Taleb, 2010]) in an effort to better understand *TdP* may be inherently impossible.

Conclusions

At present, clinicians and oversight agencies such as the FDA must study case report material for guidance despite its limitations and hazards. We describe

risk factors for methadone-associated QTc interval prolongation and *TdP* based on case reports. We believe both drug manufactures and the FDA would better protect our patients and better inform clinicians if they more readily reported drug-induced outliers using a case report format with a particular emphasis on multiple risk factors.

Reference List

- Abramson, D.W., Quinn, D.K. and Stern, T.A. (2008) Methadone-associated QTc prolongation: a case report and review of the literature. *Prim Care Comp J Clin Psychiatry* 10: 470–476.
- Agus, Z.S. (1999) Hypomagnesemia. *J Am Soc Nephrol* 10: 1616–1622.
- Almehmi, A., Malas, A.M., Yousufuddin, M. and Rosencrance, J.G. (2004) Methadone-induced torsade de pointes in a patient with normal baseline QT interval. *West Virginia M J* 100: 147–148.
- Anchersen, K., Clausen, T., Gossop, M., Hansteen, V. and Waal, H. (2009) Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. *Addiction* 104: 993–999.
- Anchersen, K., Hansteen, V., Gossop, M., Clausen, T. and Waal, H. (2010) Opioid maintenance patients with QTc prolongation: congenital long QT syndrome mutation may be a contributing risk factor. *Drug Alcohol Depend* 112: 216–219.
- Anderson, I.B. and Kearney, T.E. (2000) Use of methadone. *Western J Med* 172: 43–46.
- Ansermot, N., Albayrak, O., Schlapfer, J., Crettol, S., Croquette-Krokar, M., Bourquin, M. *et al.* (2010) Substitution of (R,S)-methadone by (R)-methadone: impact on QTc interval. *Arch Intern Med* 170: 529–536.
- Arbel, Y., Swartzon, M. and Justo, D. (2007) QT Prolongation and torsades de pointes in patients previously treated with anthracyclines. *Anti-Cancer Drugs* 18: 493–498.
- Backmund, M., Schutz, C.G., Meyer, K., Eichenlaub, D. and Soyka, M. (2003) Alcohol consumption in heroin users, methadone-substituted and codeine-substituted patients—frequency and correlates of use. *Eur Addiction Res* 9: 45–50.
- Bednar, M.M., Harrigan, E.P., Anziano, R.J., Camm, A.J. and Ruskin, J.N. (2001) The QT interval. *Prog Cardiovasc Dis* 43 (5 Suppl 1): 1–45.
- Brachmann, J., Scherlag, B.J., Rosenshtraukh, L.V. and Lazzara, R. (1983) Bradycardia-dependent triggered activity: relevance to drug-induced multiform ventricular tachycardia. *Circulation* 68: 846–856.

- Calver, L., Dunlop, A.J. and Isbister, G.K. (2012) Individual patient assessment of methadone-induced QT prolongation with digital holter recording. *J Addiction Med* 6: 92–93.
- Chang, K.-C., Huang, C.-L., Liang, H.-Y., Chang, S.-S., Wang, Y.-C., Liang, W.-M. *et al.* (2011) Gender-specific differences in susceptibility to low-dose methadone-associated QTc prolongation in patients with heroin dependence. *J Cardiovasc Electrophysiol* 23:527–533.
- Chugh, S.S., Socoteanu, C., Reinier, K., Waltz, J., Jui, J. and Gunson, K. (2008) A community-based evaluation of sudden death associated with therapeutic levels of methadone. *Am J Med* 121: 66–71.
- Crotti, L., Hu, D., Barajas-Martinez, H., De Ferrari, G.M., Oliva, A., Insolia, R. *et al.* (2012) Torsades de pointes following acute myocardial infarction: evidence for a deadly link with a common genetic variant. *Heart Rhythm* 9: 1104–1112.
- Cruciani, R.A. (2008) Methadone: To ECG or not to ECG...that is still the question. *J Pain Symptom Manage* 36: 545–552.
- De Jong, I.M. and De Ruiter, G.S. (2011) Buprenorphine as a safe alternative to methadone in a patient with acquired long QT syndrome: a case report. *Netherlands Heart J* Ahead of print 29 January 2011:
- Deamer, R.L., Wilson, D.R., Clark, D.S. and Prichard, J.G. (2001) Torsades de pointes associated with high dose levomethadyl acetate (Orlaam®). *J Addictive Dis* 20: 7–15.
- Department of Health (England) and the Devolved Administrations. (2007) *Drug Misuse and Dependence: Uk Guidelines on Clinical Management*. London: Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive.
- Drug and Alcohol Services Information System. (2006 <http://www.oas.samhsa.gov/2k6/otp/otp.htm>) Facilities operating opioid treatment programs: 2005, The DASIS Report, Vol. 36.
- Eap, C.B., Crettol, S., Rougier, J.S., Schlapfer, J., Sintra Grilo, L., Deglon, J.J. *et al.* (2007) Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in Cyp2b6 slow metabolizers. *Clin Pharmacol Ther* 81: 719–728.
- Esses, J.L., Rosman, J., Do, L.T., Schweitzer, P. and Hanon, S. (2008) Successful transition to buprenorphine in a patient with methadone-induced torsades de pointes. *J Interventional Cardiac Electrophysiol* 23: 117–119.
- Falconer, M., Molloy, D., Ingerhaug, J. and Barry, M. (2007) Methadone induced torsade de pointes in a patient receiving antiretroviral therapy. *Irish Med J* 100: 631–632.
- Gil, M., Sala, M., Anguera, I., Chapinal, O., Cervantes, M., Guma, J.R. *et al.* (2003) QT Prolongation and torsades de pointes in patients infected with human immunodeficiency virus and treated with methadone. *Am J Cardiol* 92: 995–997.
- Gintant, G.A. (2008) Preclinical torsades-de-pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk. *Pharmacol Ther* 119: 199–209.
- Gleick, J. (1987) *Chaos: making a new science*. Viking: New York.
- Hancox, J.C., Mcpate, M.J., El Harchi, A. and Zhang, Y.H. (2008) The hERG potassium channel and hERG screening for drug-induced torsades de pointes. *Pharmacol Ther* 119: 118–132.
- Hanon, S., Seewald, R.M., Yang, F., Schweitzer, P. and Rosman, J. (2010) Ventricular arrhythmias in patients treated with methadone for opioid dependence. *J Interventional Cardiac Electrophysiol* 28: 19–22.
- Hussain, T. and Ewer, A.K. (2007) Maternal methadone may cause arrhythmias in neonates. *Acta Paediatrica* 96: 768–769.
- Iskandar, S.B., Abi-Saleh, B.S., Mechleb, B.K. and Fahrig, S.A. (2007) Methadone and torsade de pointes: case report and review of the literature. *Tennessee Med* 100: 35–42.
- John, J., Amley, X., Bombino, G., Gitelis, C., Topi, B., Hollander, G. *et al.* (2010) Torsade de pointes due to methadone use in a patient with HIV and hepatitis C coinfection. *Cardiol Res Practice* 2010: 524764.
- Kang, J., Chen, X.L., Wang, H. and Rampe, D. (2003) Interactions of the narcotic l-alpha-acetylmethadol with human cardiac K⁺ channels. *Eur J Pharmacol* 458: 25–29.
- Katchman, A.N., Koerner, J., Tosaka, T., Woosley, R.L. and Ebert, S.N. (2006) Comparative evaluation of hERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. *J Pharmacol Exp Ther* 316: 1098–1106.
- Katchman, A.N., MCGroary, K.A., Kilborn, M.J., Kornick, C.A., Manfredi, P.L., Woosley, R.L. *et al.* (2002) Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. *J Pharmacol Exp Ther* 303: 688–694.
- Kornick, C.A., Kilborn, M.J., Santiago-Palma, J., Schulman, G., Thaler, H.T., Keefe, D.L. *et al.* (2003) QTc interval prolongation associated with intravenous methadone. *Pain* 105: 499–506.
- Krantz, M.J., Garcia, J.A. and Mehler, P.S. (2005) Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes. *Pharmacother* 25: 611–614.

- Krantz, M.J., Kutinsky, I.B., Robertson, A.D. and Mehler, P.S. (2003) Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes *Pharmacother* 23: 802–805.
- Krantz, M.J., Lewkowicz, L., Hays, H., Woodroffe, M.A., Robertson, A.D. and Mehler, P.S. (2002) Torsade de pointes associated with very-high-dose methadone. *Ann Intern Med* 137: 501–504.
- Krantz, M.J., Lowery, C.M., Martell, B.A., Gourevitch, M.N. and Arnsten, J.H. (2005) Effects of methadone on Qt-interval dispersion. *Pharmacother* 25: 1523–1529.
- Krantz, M.J., Rowan, S.B. and Mehler, P.S. (2005) Cocaine-related torsade de pointes in a methadone maintenance patient. *J Addictive Dis* 24: 53–60.
- Kuryshv, Y.A., Bruening-Wright, A., Brown, A.M. and Kirsch, G.E. (2010) Increased cardiac risk in concomitant methadone and diazepam treatment: pharmacodynamic interactions in cardiac ion channels. *J Cardiovasc Pharmacol* 56: 420–430.
- Lin, C., Somberg, T., Molnar, J. and Somberg, J. (2009) The effects of chiral isolates of methadone on the cardiac potassium channel I_{Kr}. *Cardiology* 113: 59–65.
- Lüthi, B., Huttner, A., Speck, R.F. and Mueller, N.J. (2007) Methadone-induced torsade de pointes after stopping lopinavir-ritonavir. *Eur J Clin Microbiol Infect Dis* 26: 367–369.
- Magnano, A.R., Talathoti, N.B., Hallur, R., Jurus, D.T., Dizon, J., Holleran, S. *et al.* (2006) Effect of acute cocaine administration on the QTc interval of habitual users. *Am J Cardiol* 97: 1244–1246.
- Makkar, R.R., Fromm, B.S., Steinman, R.T., Meissner, M.D. and Lehmann, M.H. (1993) Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. *J Am Med Assoc* 270: 2590–2597.
- Mantelli, L., Corti, V., Bini, R., Cerbai, E. and Ledda, F. (1986) [Effects of D1-methadone on the response to physiological transmitters and on several functional parameters of the isolated guinea-pig heart]. *Archives Internationales de Pharmacodynamie et de Therapie* 282: 298–313.
- Maremmani, I., Pacini, M., Cesaroni, C., Lovrecic, M., Perugi, G. and Tagliamonte, A. (2005) QTc interval prolongation in patients on long-term methadone maintenance therapy. *Eur Addiction Res* 11: 44–49.
- Martell, B.A., Arnsten, J.H., Krantz, M.J. and Gourevitch, M.N. (2005) Impact of methadone treatment on cardiac repolarization and conduction in opioid users. *Am J Cardiol* 95: 915–918.
- Miceli, J.J., Tensfeldt, T.G., Shiovitz, T., Anziano, R., O’gorman, C. and Harrigan, R.H. (2010) Effects of oral ziprasidone and oral haloperidol on QTc interval in patients with schizophrenia or schizoaffective disorder. *Pharmacother: J Hum Pharmacol Drug Ther* 30: 127–135.
- Nair, M.K., Patel, K. and Starer, P.J. (2008) Ciprofloxacin-Induced torsades de pointes in a methadone-dependent patient. *Addiction* 103: 2062–2064.
- Noorzurani, M.H., Vicknasingam, B. and Narayanan, S. (2009) Itraconazole-induced torsade de pointes in a patient receiving methadone substitution therapy. *Drug Alcohol Rev* 28: 688–690.
- Nordt, S.P., Zilberstein, J. and Gold, B. (2011) Methadone-induced torsade de pointes. *Am J Emergency Med* 29: 476.e471–476.e472.
- Pimentel, L. and Mayo, D. (2008) Chronic methadone therapy complicated by torsades de pointes: a case report. *J Emergency Med* 34: 287–290.
- Prosser, J.M., Mills, A., Rhim, E.S. and Perrone, J. (2008) Torsade de pointes caused by polypharmacy and substance abuse in a patient with human immunodeficiency virus. *Int J Emergency Med* 1: 217–220.
- Puri, R., Roberts-Thomson, K.C. and Young, G.D. (2009) HIV and long QT syndrome—cause or coincidence. *Int J Cardiol* 133: e9–e10.
- Raschi, E., Ceccarini, L., De Ponti, F. and Recanatini, M. (2009) Herg-related drug toxicity and models for predicting herg liability and QT prolongation. *Exp Opin Drug Metab Toxicol* 5: 1005–1021.
- Redfern, W.S., Carlsson, L., Davis, A.S., Lynch, W.G., Mackenzie, I. and Palethrope, S. (2003) Relationship between preclinical electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. *Cardiovasc Res* 58: 32–45.
- Reinhold, J.A., Sanoski, C.A., Russo, A.M., Cooper, J.M. and Spinler, S.A. (2009) Torsades de pointes associated with methadone and voriconazole. *Br Med J Case Reports Epub* 2009 December 22:
- Routhier, D.D., Katz, K.D. and Brooks, D.E. (2007) QTc prolongation and torsades de pointes associated with methadone therapy. *J Emergency Med* 32: 275–278.
- Roxane Laboratories. (2003) Dolphine hydrochloride (methadone hydrochloride tablets) package insert.
- Roy, A.K., Mccarthy, C., Kiernan, G., Mcgorrigan, C., Keenan, E., Mahon, N.G. *et al.* (2012) Increased incidence of QT interval prolongation in a population receiving lower doses of methadone maintenance therapy. *Addiction* 107: 1132–1139.

- Sanguinetti, M.C., Jiang, C., Curran, M.E. and Keating, M.T. (1995) A mechanistic link between an inherited and an acquired cardiac arrhythmia: hERG encodes the I_{Kr} potassium channel. *Cell* 81: 299–307.
- Sanguinetti, M.C. and Mitcheson, J.S. (2005) Predicting drug-HERG channel interactions that cause acquired long QT syndrome. *Trend Pharmacol Sci* 26: 119–124.
- Sekine, R., Obbens, E.a.M.T., Coyle, N. and Inturrisi, C.E. (2007) The successful use of parenteral methadone in a patient with a prolonged QTc interval. *J Pain Symptom Manage* 34: 566–569.
- Sticherling, C., Schaer, B.A., Ammann, P., Maeder, M. and Osswald, S. (2005) Methadone-induced torsade de pointes tachycardias. *Swiss Medical Weekly* 135: 282–285.
- Taleb, N.N. (2010) *The black swan*, 2nd Edition. Random House: New York.
- Thanavaro, K.L. and Thanavaro, J.L. (2011) Methadone-induced torsades de pointes: a twist of fate. *Heart Lung: J Acute Crit Care* 40: 448–453.
- Trudeau, M.C., Warmke, J.W., Ganetzky, B. and Robertson, G.A. (1995) HERG, a human inward rectifier in the voltage-gated potassium channel family. *Science* 269: 92–95.
- Vieweg, W.V., Hasnain, M., Howland, R.H., Hettema, J.M., Kogut, C., Wood, M.A. et al. (2012) Citalopram, QTc interval prolongation and torsade de pointes. how should we apply the recent FDA ruling? *Am J Med* 125: 859–868.
- Vieweg, W.V.R. (2003) New generation antipsychotic drugs and QTc interval prolongation. *Prim Care Comp J Clin Psychiatry* 5: 205–215.
- Vieweg, W.V.R., Hasnain, M., Wood, M.A., Fernandez, A., Lesnefsky, E.J. and Pandurangi, A.K. (2011) Cardiometabolic risks of antidepressant and antipsychotic drugs, part 1. proarrhythmic risks of antidepressant and antipsychotic drugs. *Psychiatric Times* 28 (April): 50–55.
- Vieweg, W.V.R., Schneider, R.K. and Wood, M.A. (2005) Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine. *Acta Psychiatrica Scandinavica* 112: 319–323.
- Vieweg, W.V.R. and Wood, M.A. (2004) Tricyclic antidepressants, QT interval prolongation and torsade de pointes *Psychosomatics* 45: 371–377.
- Vieweg, W.V.R., Wood, M.A., Fernandez, A., Beatty-Brooks, M., Hasnain, M. and Pandurangi, A.K. (2009) Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. *Drugs Aging* 26: 997–1012.
- Viskin, S., Justo, D., Halkin, A. and Zeltser, D. (2003) Long QT syndrome caused by noncardiac drugs. *Progress in Cardiovascular Diseases* 45: 415–427.
- Vodoz, J.F., Jaquier, F. and Lamy, O. (2003) Torsade de pointes: a severe and unknown adverse effect in a patient taking methadone. *Praxis (Bern 1994)* 92: 1748–1750.
- Walker, P.W., Klein, D. and Kasza, L. (2003) High dose methadone and ventricular arrhythmias: a report of three cases. *Pain* 103: 321–324.
- Witchel, H.J. and Hancox, J.C. (2000) Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current. *Clin Exp Pharmacol Physiol* 27: 753–766.
- Wong, S. and Roberts, J. (2007) Case files of the drexel university medical toxicology fellowship: methadone-induced QTc prolongation. *J Med Toxicol* 3: 190–194.
- Zeltser, D., Justo, D., Halkin, A., Prokhorov, V., Heller, K. and Viskin, S. (2003) Torsade de pointes due to noncardiac drugs. most patients have easily identifiable risk factors. *Medicine* 82: 282–290.
- Zickler, P. (2000) Gender differences in prevalence of drug abuse traced to opportunities to use. *NIDA Notes* 15 Number 4: 1–2.
- Zunkler, B.J. and Wos-Maganga, M. (2010) Comparison of the effects of methadone and heroin on Human ether-a-go-go-related gene channels. *Cardiovasc Toxicol* 10: 161–165.